Protalix BioTherapeutics(PLX) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - For the full year 2025, total revenues from selling goods were $51.8 million, a modest decrease compared to 2024, driven by changes in quantities sold to Chiesi's inventory and a change in average net selling price due to increased commercial patients in Europe [8] - The company recorded a net loss of $6.6 million in 2025 compared to a net income of $2.9 million in 2024, reflecting increased investment in the clinical pipeline [10] - As of December 31, 2025, the company held $30.3 million in cash equivalents and short-term bank deposits, with a projected cash balance of approximately $50 million by early April 2026 [10] Business Line Data and Key Metrics Changes - Revenues from Chiesi are projected to be approximately $33 million-$35 million in 2026, representing growth of more than 50% [10] - Revenues from Elelyso are expected to be approximately $20 million-$23 million in 2026 [10] - Revenues from license and R&D services increased to $0.9 million, mainly related to agreements with Chiesi [8] Market Data and Key Metrics Changes - The Fabry market is projected to reach approximately $3.4 billion by 2030, with Elfabrio's differentiated profile enhancing its competitive positioning [6] - The approval of the every four weeks dosing regimen in Europe is expected to significantly enhance Elfabrio's market position [5] Company Strategy and Development Direction - The company aims to execute its strategy comfortably, including clinical trials, supported by a strong cash position and projected revenue growth [4][12] - The company is advancing its pipeline with PRX-115 for uncontrolled gout and PRX-119 for renal conditions, targeting high unmet needs [6][7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term trajectory of the Fabry market and the potential for Elfabrio to capture a significant market share [5][12] - The company anticipates a productive 2026, driven by a growing number of patients on Elfabrio and a strong financial position [12] Other Important Information - The European Commission approved the 2 mg/kg every four weeks dosing regimen for Elfabrio, which is expected to enhance long-term management for patients with Fabry disease [3][4] - The company expects to continue increasing R&D investment as its clinical programs advance [9] Q&A Session Summary Question: Insights on marketing initiatives for Elfabrio in the U.S. and the impact of the new dosing regimen in Europe - Management highlighted that Chiesi is implementing various promotional activities to increase patient numbers and that the new dosing regimen provides a competitive edge [15][17] Question: Positioning of PRX-115 in the gout market - Management discussed the potential competitive advantages of PRX-115, including improved dosing frequency and safety, and projected a significant market opportunity for uncontrolled gout [18][22] Question: Target indications for PRX-119 and potential commercial opportunities - Management indicated that they are targeting high unmet need renal conditions and will provide updates on specific indications in the future [23][24] Question: Timeline for rollout of the four-week dosing regimen for Elfabrio in Europe - Management stated that the rollout will vary by country, with expectations for effects to start in the second half of 2026 [27][31]